Modality
Gene Editing
MOA
JAK1i
Target
TYK2
Pathway
Apoptosis
CeliacACC
Development Pipeline
Preclinical
Feb 2022
→ Oct 2027
PreclinicalCurrent
NCT05248365
1,229 pts·Celiac
2022-02→2027-10·Recruiting
NCT06055751
55 pts·ACC
2025-08→2025-07·Not yet recruiting
1,284 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-07-099mo agoInterim· ACC
2027-10-241.6y awayInterim· Celiac
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
Preclinical
Recruit…
Preclinical
Not yet…
Catalysts
Interim
2025-07-09 · 9mo ago
ACC
Interim
2027-10-24 · 1.6y away
Celiac
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05248365 | Preclinical | Celiac | Recruiting | 1229 | BodyWt |
| NCT06055751 | Preclinical | ACC | Not yet recr... | 55 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| ROI-1081 | Roivant Sciences | Phase 1/2 | PI3Kα | |
| COR-9566 | Corcept | Approved | TYK2 | |
| SND-9531 | Syndax | Phase 3 | TYK2 |